D-mannose is a natural, bioactive monosaccharide. It is found in many plants, animals, but also in humans. As an essential component of human polysaccharides and glycoproteins, D-mannose is involved in various complex metabolism pathways of our body.1 The important role of D-mannose can for example be seen in patients suffering from congenital glycosylation deficiency 1b (CDG 1b).2 The incorporation of D-mannose in glycoproteins is disordered in these patients. CDG 1b is characterized by bleeding diathesis, increased risk for thrombotic events, abnormal liver function, hyperinsulinism and chronic diarrhoea.1 Oral supplementation with D-mannose has been shown to alleviate symptoms allowing affected patients to live an almost “normal” life.2, 3, 4


D-mannose is partly excreted through the kidneys. Preclinical studies show that D-mannose may treat or prevent urinary tract infections by functioning as a decoy for pathogens.5, 6, 7 E. coli bacteria directly bind to D-mannose and thus can block their adhesion to body tissue. In this way, it helps the bacteria to leave the body through the urine and lowers the risk of an urinary tract infection.

Furthermore, D-mannose is used in the development of novel cancer drugs. Here, D-mannose is part of nanoscaffolds.8 D-mannose containing pharmaceuticals are highly investigated candidates for immune and gene therapy.8

Jennewein Biotechnologie produces D-mannose on a commercial scale under FSSC 22000 and ISO 9001.


  1. Sharma V, et al. (2014) Mannose metabolism: more than meets the eye. Biochem Biophys Res Commun. 2014; 453: 220-228
  2. Niehues R, et al. (1998) Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. J Clin Invest. 1998; 101: 1414-1420
  3. Harms HK, et al. (2002) Oral mannose therapy persistently corrects the severe clinical symptoms and biochemical abnormalities of phosphomannose isomerase deficiency. Acta Paediatr. 2002; 91: 1065-1072
  4. Westphal V, et al. (2001) Genetic and metabolic analysis of the first adult with congenital disorder of glycosylation type Ib: long-term outcome and effects of mannose supplementation. Mol Genet Metab. 2001; 73: 77-85
  5. Domenici L, et al. (2016) D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci. 2016; 20: 2920-2925
  6. Vicariotto F, et al. (2014) Effectiveness of an association of a cranberry dry extract, D-mannose, and the two microorganisms Lactobacillus plantarum LP01 and Lactobacillus paracasei LPC09 in women affected by cystitis: a pilot study. J Clin Gastroenterol. 2014; 48: 96-101
  7. Kranjčec B, et al. (2014) D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014; 32: 79-84
  8. Hu J, et al. (2018) Mannose-Functionalized Nanoscaffolds for Targeted Delivery in Biomedical Applications. Chem Asian J. 2018; 22: 3448-3459

Please contact us for further details: